The company has reported zero revenue for multiple consecutive quarters, with R&D expenses consistently exceeding $10 million per period, driving deep operating losses.
| Sales/Revenue | 0 | 0 | 1.89M | 19.94M | 16.4M | 0 | 0 | 0 |
| Revenue Growth % | -100% | -100% | -90.55% | 21.6% | - | - | - | - |
| Cost of Goods Sold | 804K | 1.63M | 1.81M | 1.76M | 2.51M | 0 | 777K | 463K |
| COGS % of Revenue | - | - | 96.23% | 8.85% | 15.3% | - | - | - |
| Gross Profit | -804K | -1.63M | 71K | 18.18M | 13.89M | 0 | -777K | -463K |
| Gross Margin % | - | - | 3.77% | 91.15% | 84.7% | - | - | - |
| Gross Profit Growth % | - | -2401.41% | -99.61% | 30.87% | - | 100% | -67.82% | - |
| Operating Expenses | 50.85M | 59.04M | 73.67M | 58.68M | 69.95M | 50.09M | 21.63M | 9.94M |
| OpEx % of Revenue | - | - | 3907.96% | 294.25% | 426.48% | - | - | - |
| Selling, General & Admin | 16.07M | 15.85M | 19.05M | 18.67M | 21.5M | 14.82M | 5.76M | 3.6M |
| SG&A % of Revenue | - | - | 1010.34% | 93.62% | 131.1% | - | - | - |
| Research & Development | 39.89M | 44.83M | 56.43M | 41.78M | 53.76M | 35.27M | 16.64M | 6.34M |
| R&D % of Revenue | - | - | 2993.85% | 209.48% | 327.79% | - | - | - |
| Other Operating Expenses | -1.41M | -1.63M | -1.81M | -1.76M | -5.32M | 0 | -777K | 0 |
| Operating Income | -51.65M | -60.68M | -73.59M | -40.5M | -56.06M | -50.09M | -22.4M | -9.94M |
| Operating Margin % | - | - | -3904.19% | -203.09% | -341.78% | - | - | - |
| Operating Income Growth % | - | 17.55% | -81.7% | 27.75% | -11.92% | -123.56% | -125.48% | - |
| EBITDA | -50.05M | -59.04M | -71.78M | -38.74M | -53.55M | -49.87M | -21.63M | -9.47M |
| EBITDA Margin % | - | - | -3807.96% | -194.25% | -326.48% | - | - | - |
| EBITDA Growth % | 31.11% | 17.74% | -85.29% | 27.65% | -7.37% | -130.6% | -128.3% | - |
| D&A (Non-Cash Add-back) | 1.61M | 1.63M | 1.81M | 1.76M | 2.51M | 216K | 777K | 463K |
| EBIT | -48.38M | -60.68M | -65.86M | -34.23M | -53.81M | -50.09M | -15.04M | -9.88M |
| Net Interest Income | -2.83M | -2.17M | 2.02M | 4.28M | 1.91M | 104K | 101K | 0 |
| Interest Income | 1.85M | 3.11M | 6.67M | 7.42M | 1.91M | 104K | 101K | 372K |
| Interest Expense | 4.68M | 5.27M | 4.66M | 3.14M | 0 | 0 | 0 | 372K |
| Other Income/Expense | -4.61M | -145K | 3.08M | 3.13M | 2.25M | 104K | 7.36M | -312K |
| Pretax Income | -56.27M | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M | -15.04M | -10.25M |
| Pretax Margin % | - | - | -3740.85% | -187.37% | -328.09% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -56.27M | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M | -14.94M | -10.99M |
| Net Margin % | - | - | -3740.85% | -187.37% | -328.09% | - | - | - |
| Net Income Growth % | 22.3% | 13.75% | -88.7% | 30.56% | -7.66% | -234.58% | -35.93% | - |
| Net Income (Continuing) | -56.27M | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M | -15.04M | -10.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.14 | -1.33 | -1.63 | -1.05 | -1.86 | -10.94 | -0.98 | -0.38 |
| EPS Growth % | 26.22% | 18.4% | -55.24% | 43.55% | 83% | -1016.33% | -157.89% | - |
| EPS (Basic) | - | -1.32 | -1.63 | -1.05 | -1.86 | -10.94 | -0.98 | -0.38 |
| Diluted Shares Outstanding | 49.39M | 46.81M | 43.86M | 35.65M | 28.86M | 18.45M | 28.66M | 28.66M |
| Basic Shares Outstanding | 48.6M | 46.02M | 43.33M | 35.65M | 28.86M | 18.45M | 28.66M | 28.66M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical Trial Funding Gap
As indicated by the most recent quarterly filings, Werewolf Therapeutics has reported zero revenue for several consecutive periods, underscoring its status as a pre-commercial entity whose financial trajectory is entirely dependent on the timing of milestone payments rather than consistent, recurring product-based commercial sales.
The lack of revenue growth is not indicative of operational failure but rather the inherent nature of a clinical-stage biotech firm. Investors should monitor future partnership agreements as the primary mechanism for revenue generation, as the current absence of top-line figures suggests a reliance on external capital to fund ongoing research.
Based on the provided financial data, R&D expenses remain the dominant cost driver, frequently exceeding $10 million per quarter, which highlights the company's aggressive investment in advancing its INDUKINE platform through early-stage clinical trials despite the absence of any offsetting commercial revenue streams.
The concentration of spending in R&D suggests that management is prioritizing the clinical validation of its lead assets over near-term profitability. This cost structure appears rigid, as the company must maintain high laboratory and clinical trial expenditures to meet its development milestones, leaving little room for expense discipline.
According to the income statement history, operating losses have consistently tracked with R&D spending, with quarterly operating losses often exceeding $15 million, demonstrating that the company currently lacks the operating leverage necessary to scale its business model without significant external capital injections or successful licensing.
The persistent negative operating margin reflects the high fixed costs associated with drug development. Without a commercial product to provide scale, the company's operating leverage will likely remain strained, necessitating careful monitoring of how management balances trial expansion with the preservation of its limited cash reserves.
Financial statements reveal a cash position of approximately $58 million, which, when viewed against the historical quarterly burn rate, suggests a limited operational runway that may force management into dilutive financing or unfavorable partnership terms if clinical data readouts do not provide immediate valuation catalysts.
Short-term investors should be wary of the potential for a capital raise, which could significantly dilute existing shareholders. Furthermore, the reliance on protease-cleavable linkers introduces a binary risk where any failure in the clinical efficacy of the INDUKINE platform would likely result in a rapid deterioration of the company's remaining financial viability.
Quick answers to the most common questions about buying HOWL stock.
For fiscal year 2025, Werewolf Therapeutics, Inc. (HOWL) reported total revenue of $0.0M.
Werewolf Therapeutics, Inc. (HOWL) reported a net loss of $60.8M for the fiscal year ending 2025.